Louis R, Schleich F, Barnes PJ,. Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med 2012; 33: 531-41.
Chung WH, Chen YF, Hsu JC, Yang WT, Chen SC, Chiang JY,. Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population based case control study. Int J Clin Pract 2014; 68: 1193-9.
Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ,. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013; 68: 1105-13.
Lee CH, Lee MC, Shu CC, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013; 13: 194.
Brassard P, Suissa S, Kezouh A, Ernst P,. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011; 183: 675-8.
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013; 346: f3306.
Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med 2013; 273: 584-94.
Suissa S, Patenaude V, Lapi F, Ernst P,. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-36.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK,. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J,. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-80.
Corhay JL, Vincken W, Schlesser M, Bossuyt P, Imschoot J,. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. Int J Clin Pract 2013; 67: 1294-301.
Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-8.
Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-13.
Sethi S, Murphy TF,. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-65.
Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67: 1075-80.
Price D, Yawn B, Brusselle G, Rossi A,. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013; 22: 92-100.
Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-92.
Greening AP, Ind PW, Northfield M, Shaw G,. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-24.
Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-11.
Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-44.
Reddel HK,. Treating according to asthma control: does it work in real life? Clin Chest Med 2012; 33: 505-17.
Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R,. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62: 1043-9.
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-21.
Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count >/=3% in a cohort of unselected patients with asthma. Thorax 2010; 65: 1039-44.
Jatakanon A, Lim S, Barnes PJ,. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161: 64-72.
Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115: 720-7.
Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082-90.
